Praxis Precision Medicines Shares Rise After FDA Accepts New Drug Application

Dow Jones

04/14

By Christopher Kuo

Praxis Precision Medicines shares rose after the Food and Drug Administration accepted its new drug application for ulixacaltamide HCl in the treatment of essential tremor in adults.

Shares of the biopharmaceutical company rose 7.9% on Tuesday to $342.09. The company's shares are up 16% year to date.

The Ulixacaltamide HCl drug is designed to block the abnormal activity of neurons that correlates with tremor activity, which is a neurological disorder involving rhythmic shaking, the company said.

The drug went through a Phase 3 program with two studies of adults and received breakthrough therapy designation from the FDA in 2025. The FDA has set a target action date of Jan. 29, 2027, the company said.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

April 14, 2026 10:32 ET (14:32 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2627442700"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627442700\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627442700?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627442700","market":"us","top_or_hot":-1,"title":"Praxis Precision Medicines Shares Rise After FDA Accepts New Drug Application","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> shares rose after the Food and Drug Administration accepted its new drug application for ulixacaltamide HCl in the treatment of essential tremor in adults. \n</p>\n<p>\n  Shares of the biopharmaceutical company rose 7.9% on Tuesday to $342.09. The company's shares are up 16% year to date. \n</p>\n<p>\n  The Ulixacaltamide HCl drug is designed to block the abnormal activity of neurons that correlates with tremor activity, which is a neurological disorder involving rhythmic shaking, the company said. \n</p>\n<p>\n  The drug went through a Phase 3 program with two studies of adults and received breakthrough therapy designation from the FDA in 2025. The FDA has set a target action date of Jan. 29, 2027, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 14, 2026 10:32 ET (14:32 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Praxis Precision Medicines Shares Rise After FDA Accepts New Drug Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPraxis Precision Medicines Shares Rise After FDA Accepts New Drug Application\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-04-14 22:32</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> shares rose after the Food and Drug Administration accepted its new drug application for ulixacaltamide HCl in the treatment of essential tremor in adults. \n</p>\n<p>\n  Shares of the biopharmaceutical company rose 7.9% on Tuesday to $342.09. The company's shares are up 16% year to date. \n</p>\n<p>\n  The Ulixacaltamide HCl drug is designed to block the abnormal activity of neurons that correlates with tremor activity, which is a neurological disorder involving rhythmic shaking, the company said. \n</p>\n<p>\n  The drug went through a Phase 3 program with two studies of adults and received breakthrough therapy designation from the FDA in 2025. The FDA has set a target action date of Jan. 29, 2027, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 14, 2026 10:32 ET (14:32 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJT1NW94.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2627442700","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627442700","pubTimestamp":1776177120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Praxis Precision Medicines shares rose after the Food and Drug Administration accepted its new drug application for ulixacaltamide HCl in the treatment of essential tremor in adults.Shares of the biopharmaceutical company rose 7.9% on Tuesday to $342.09. The company's shares are up 16% year to date.The drug went through a Phase 3 program with two studies of adults and received breakthrough therapy designation from the FDA in 2025. The FDA has set a target action date of Jan. 29, 2027, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4588":"碎股","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4585":"ETF&股票定投概念","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LABU":"三倍做多标普生物-Direxion","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","PRAX":"Praxis Precision Medicines, Inc.","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC"},"translate_title":"FDA接受新药申请后Praxis Precision Medicines股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"PRAX":1.5},"content_text":"By Christopher Kuo \n\n\n \n\n\nPraxis Precision Medicines shares rose after the Food and Drug Administration accepted its new drug application for ulixacaltamide HCl in the treatment of essential tremor in adults. \n\n\n  Shares of the biopharmaceutical company rose 7.9% on Tuesday to $342.09. The company's shares are up 16% year to date. \n\n\n  The Ulixacaltamide HCl drug is designed to block the abnormal activity of neurons that correlates with tremor activity, which is a neurological disorder involving rhythmic shaking, the company said. \n\n\n  The drug went through a Phase 3 program with two studies of adults and received breakthrough therapy designation from the FDA in 2025. The FDA has set a target action date of Jan. 29, 2027, the company said. \n\n\n \n\n\n   Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 14, 2026 10:32 ET (14:32 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}